<!DOCTYPE html><html><head><title>Management of acute atrial fibrillation and atrial flutter in non-pregnant hospitalized adults.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Guideline Title
</h3>
<div class='FieldValue'>
<div class="content_title">Management of acute atrial fibrillation and atrial flutter in non-pregnant hospitalized adults.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>University of Michigan Health System. Management of acute atrial fibrillation and atrial flutter in non-pregnant hospitalized adults. Ann Arbor (MI): University of Michigan Health System; 2014 May. 26 p.  [30 references]</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Recommendations
</h2>
<div class='field field_text'>
<h3>
Major Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><em>Note from the University of Michigan Health System (UMHS) and the National Guideline Clearinghouse (NGC)</em></strong>: The following guidance was current as of May 2014. Because UMHS occasionally releases minor revisions to its guidance based on new information, users may wish to consult the <a href="http://www.med.umich.edu/1info/FHP/practiceguides/afib.html" title="UMHS Web site">original guideline document</a> for the most current version.</p>
<p><strong>Note from NGC</strong>: The following key points summarize the content of the guideline. Refer to the full text of the original guideline document for detailed information on each of the screening procedures.</p>
<p>The strength of recommendation (I-III) and levels of evidence (A-D) are defined at the end of the "Major Recommendations" field.</p>
<p><span style="text-decoration: underline;"><strong>Key Points</strong></span></p>
<p><strong>Clinical Presentation</strong></p>
<p>Patients presenting with palpitations, irregular pulse, chest pain, dyspnea, fatigue, lightheadedness, syncope, cardio-embolic disease and new or recurrent heart failure should be evaluated for atrial fibrillation/atrial flutter (AF/AFL). While AF may be asymptomatic and found incidentally, AFL is usually highly symptomatic.</p>
<p><strong>Diagnosis</strong></p>
<p>Electrocardiogram (ECG) is essential in the diagnosis of AF/AFL. The initial evaluation is summarized in Table 1 in the original guideline document and should include:</p>
<ul style="list-style-type: disc;">
    <li>Physical exam </li>
    <li>Laboratory evaluation: complete blood count (CBC), basic metabolic profile, magnesium, thyroid-stimulating hormone, and cardiac enzymes as indicated </li>
    <li>Imaging: chest X-ray, echocardiogram </li>
    <li>Continuous telemetry monitoring in the hospital </li>
</ul>
<p><strong>Treatment</strong></p>
<p>Initial treatment of AF/AFL depends on hemodynamic stability.</p>
<p><em>Unstable AF/AFL</em> (refer to Figure 1 in the original guideline document):</p>
<ul style="list-style-type: disc;">
    <li>Begin resuscitation and consider other conditions contributing to instability. </li>
    <li>If instability due to AF/AFL - immediate direct current cardioversion. </li>
</ul>
<p><em>Stable AF/AFL</em> (refer to Figure 2 in the original guideline document):</p>
<ul style="list-style-type: disc;">
    <li>For emergency department (ED) patients: Screen for early cardioversion in the ED (refer to Figure 4 in the original guideline document). </li>
    <li>Administer rate controlling agents as indicated (refer to Table 4 in the original guideline document) &ndash; <em>[I, B]</em>.
    <ul style="list-style-type: disc;">
        <li>Electrophysiology (EP) consult for uncontrolled rate despite adequate trial of rate controlling agents. </li>
    </ul>
    </li>
    <li>Consider the appropriateness of a rhythm control strategy (refer to Table 3 in the original guideline document) &ndash; <em>[I, B]</em>.
    <ul style="list-style-type: disc;">
        <li>If rhythm control strategy is appropriate/desired, consult EP and start immediate anticoagulation (refer to Figure 3 in the original guideline document). </li>
    </ul>
    </li>
    <li>Consider anticoagulation based on CHA<sub>2</sub>DS<sub>2</sub>-VAS<sub>c</sub> score (refer to Table 2 and Figure 3 in the original guideline document) &ndash; <em>[I, A]</em>.
    <ul style="list-style-type: disc;">
        <li>The choice of anticoagulant will depend on the patient's clinical circumstances and renal function (refer to Figure 3 in the original guideline document). </li>
        <li>Obtain Neurology consult prior to initiation of anticoagulation for patients with recent ischemic stroke within the prior two weeks. </li>
        <li>Patients with valvular disease and those requiring concomitant treatment with dual antiplatelet therapy should be anticoagulated with warfarin. </li>
        <li>Target-specific oral anticoagulants are preferred over warfarin in many cases. </li>
    </ul>
    </li>
</ul>
<p><strong><span style="text-decoration: underline;">Definitions</span></strong>:</p>
<p><strong>Levels of Evidence</strong></p>
<ol style="list-style-type: upper-alpha;">
    <li>Randomized controlled trials </li>
    <li>Controlled trials, no randomization </li>
    <li>Observational trials </li>
    <li>Opinion of expert panel </li>
</ol>
<p><strong>Strength of Recommendation</strong></p>
<ol style="list-style-type: upper-roman;">
    <li>Generally should be performed </li>
    <li>May be reasonable to perform </li>
    <li>Generally should not be performed </li>
</ol></div>
</div>

</div>
<div class='field field_text'>
<h3>
Clinical Algorithm(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The following algorithms are provided in the original guideline document:</p>
<ul style="list-style-type: disc;">
    <li>Acute management of UNSTABLE atrial fibrillation and atrial flutter (AF/AFL) </li>
    <li>Acute management of STABLE atrial fibrillation and atrial flutter with rapid ventricular response </li>
    <li>Management of anticoagulation therapy in atrial fibrillation and atrial flutter </li>
    <li>Emergency department screening for early cardioversion of atrial fibrillation and atrial flutter </li>
</ul>
<p>An algorithm titled "Management of acute atrial fibrillation/flutter after thoracic surgery" is also provided in Appendix C in the original guideline document.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Scope
</h2>
<div class='field field_text'>
<h3>
Disease/Condition(s)
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Atrial fibrillation </li>
    <li>Atrial flutter </li>
</ul>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Guideline Category
</h3>
<div class='FieldValue'>
Diagnosis
</div>
<div class='FieldValue'>
Evaluation
</div>
<div class='FieldValue'>
Management
</div>
<div class='FieldValue'>
Screening
</div>
<div class='FieldValue'>
Treatment
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Clinical Specialty
</h3>
<div class='FieldValue'>
Cardiology
</div>
<div class='FieldValue'>
Critical Care
</div>
<div class='FieldValue'>
Emergency Medicine
</div>
<div class='FieldValue'>
Family Practice
</div>
<div class='FieldValue'>
Geriatrics
</div>
<div class='FieldValue'>
Internal Medicine
</div>
<div class='FieldValue'>
Thoracic Surgery
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Intended Users
</h3>
<div class='FieldValue'>
Advanced Practice Nurses
</div>
<div class='FieldValue'>
Emergency Medical Technicians/Paramedics
</div>
<div class='FieldValue'>
Hospitals
</div>
<div class='FieldValue'>
Nurses
</div>
<div class='FieldValue'>
Physician Assistants
</div>
<div class='FieldValue'>
Physicians
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Objective(s)
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>To provide an evidence-based blue print for the acute care of patients with atrial fibrillation (AF) and atrial flutter (AFL) at the University of Michigan Health System </li>
    <li>To assure consistent care delivery for patients with AF across the inpatient services </li>
</ul>
</div>

</div>
<div class='field field_text'>
<h3>
Target Population
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Adult non-pregnant hospitalized patients with atrial fibrillation and atrial flutter</p>
<p class="Note"><strong>Note</strong>: These guidelines are applicable to all inpatients with notable exception of patients on the Cardiology, Cardiac Intensive Care or Cardiac Surgery Services.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Interventions and Practices Considered
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Diagnosis/Evaluation</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Assessment of signs and symptoms </li>
    <li>Electrocardiogram (ECG) </li>
    <li>Physical exam </li>
    <li>Laboratory tests </li>
    <li>Imaging (chest X-ray, echocardiogram) </li>
    <li>Continuous telemetry monitoring </li>
</ol>
<p><strong>Treatment/Management</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Resuscitation and consideration of other conditions contributing to instability </li>
    <li>Direct current cardioversion </li>
    <li>Rate-controlling agents (calcium channel blockers, beta-blockers, amiodarone, digoxin) </li>
    <li>Electrophysiology (EP) consultation </li>
    <li>Anticoagulation based on CHA<sub>2</sub>DS<sub>2</sub>-VASc score </li>
    <li>Neurology consultation </li>
</ol></div>
</div>

</div>
<div class='field field_text'>
<h3>
Major Outcomes Considered
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Heart rate control </li>
    <li>Rhythm control </li>
    <li>Mortality rate </li>
    <li>Stroke rate </li>
    <li>Bleeding rate </li>
</ul>
</div>

</div>

</div>
<div class='section'>
<h2>Methodology
</h2>
<div class='field field_picklist-many'>
<h3>
Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
Searches of Electronic Databases
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The literature search for this guideline was conducted prospectively using the major keywords of "atrial fibrillation" or "atrial flutter." Results were limited to humans, and published in the English language, for dates ranging from January 2011 to March 2013 on Medline. There were no limits on age groups. Results were limited to guidelines, clinical trials, and cohort studies.</p>
<p>Additional key words included: rate control, rhythm control, procedures, established drug therapies, novel drug therapies, clinical classification systems/risk calculators, and post-operative.</p>
<p>The search was conducted in components each keyed to a specific causal link in a formal problem structure (available upon request). The search was supplemented with very recent clinical trials known to expert members of the panel. The search was a single cycle.</p>
<p>Within the Cochrane systematic reviews, 35 reviews were found for the terms "atrial fibrillation" and "atrial flutter." Within the National Guideline Clearinghouse, these terms returned 13 guidelines.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Number of Source Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not stated</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Assess the Quality and Strength of the Evidence
</h3>
<div class='FieldValue'>
Weighting According to a Rating Scheme (Scheme Given)
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Level of Evidence</strong></p>
<ol style="list-style-type: upper-alpha;" start="1">
    <li>Randomized controlled trials </li>
    <li>Controlled trials, no randomization </li>
    <li>Observational trials </li>
    <li>Opinion of expert panel </li>
</ol></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
Systematic Review
</div>

</div>
<div class='field field_text'>
<h3>
Description of the Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not stated</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
Expert Consensus
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Conclusions were based on prospective randomized clinical trials if available, to the exclusion of
other data; if randomized controlled trials were not available,
observational studies were admitted to consideration. If no such data
were available for a given link in the problem formulation, expert
opinion was used to estimate effect size.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Strength of Recommendation</strong></p>
<ol style="list-style-type: upper-roman;">
    <li>Generally should be performed </li>
    <li>May be reasonable to perform </li>
    <li>Generally should not be performed </li>
</ol></div>
</div>

</div>
<div class='field field_text'>
<h3>
Cost Analysis
</h3>
<div class='FieldValue'>
<div class="content_para"><p>A formal cost analysis was not performed and published analyses were not reviewed.</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Method of Guideline Validation
</h3>
<div class='FieldValue'>
Internal Peer Review
</div>

</div>
<div class='field field_text'>
<h3>
Description of Method of Guideline Validation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Drafts of this guideline were reviewed in clinical conferences and by distribution for comment within
departments and divisions of the University of Michigan Health System to which the content is most relevant:
Emergency Medicine, General Medicine, Infectious Disease, Neurosurgery, Cardiology, Cardiac Surgery, Stroke, Pharmacy Services, and Thoracic Surgery. Medication recommendations were reviewed by the
Pharmacy and Therapeutics Committee. The final version was endorsed by the Clinical Practice Committee of the University of Michigan Faculty Group Practice and the Executive Committee for Clinical Affairs of the University of Michigan Hospitals and Health Centers.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Recommendations
</h2>
<div class='field field_text'>
<h3>
Type of Evidence Supporting the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The type of supporting evidence is identified and graded for selected recommendations (see the "Major Recommendations" field).</p>
<p>Conclusions were based on prospective randomized clinical trials
(RCTs) if available, to the exclusion of other data; if RCTs were not
available, observational studies were admitted to consideration. If no
such data were available for a given link in the problem formulation,
expert opinion was used to estimate effect size.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Benefits/Harms of Implementing the Guideline Recommendations
</h2>
<div class='field field_text'>
<h3>
Potential Benefits
</h3>
<div class='FieldValue'>
<div class="content_para"><p>It is hoped that standardization of care will result in improved patient outcomes, shorter length of hospital stay, lower readmission rates, and overall cost savings for the system.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Potential Harms
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Calcium channel blockers can cause hypotension and atrioventricular (AV) nodal block. </li>
    <li>Beta-blockers can cause hypotension and AV nodal block. Use metoprolol with caution in patients with decompensated heart failure. </li>
    <li>Amiodarone can cause hypotension (when given intravenously), pulmonary toxicity (so patients with severe lung disease are poor candidates for long-term administration), hepatic toxicity, hypo/hyperthyroidism, and ocular side effects. </li>
    <li>Digoxin can cause AV nodal block and digoxin toxicity. </li>
    <li>Anticoagulants are associated with risk of bleeding. </li>
</ul>
<p>Refer to Table 4 and Appendices A and B in the original guideline document for more information on specific drugs.</p>
</div>

</div>

</div>
<div class='section'>
<h2>Contraindications
</h2>
<div class='field field_text'>
<h3>
Contraindications
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Drugs contraindicated in patients with accessory pathways include digoxin, and non-dihydropyridine calcium channel antagonists (e.g., verapamil, diltiazem), which slow conduction across the atrioventricular (AV) node, and can result in paradoxical acceleration of the ventricular rate, hypotension, or ventricular fibrillation. </li>
    <li>Avoid metoprolol in patients with bronchoconstriction or emphysema. Avoid esmolol and propranolol in patients with acute or active airway obstruction/bronchoconstriction or decompensated heart failure. </li>
    <li>Procainamide should be held for systolic blood pressure &lt;90 mmHg, and is contraindicated in patient with renal failure (creatinine clearance &lt;30), severe liver disease, lupus, or baseline hypotension. </li>
</ul>
<p>Table 4 and Appendix A in the original guideline document provide a review of drugs used in atrial flutter/acute atrial fibrillation and include additional information about contraindications.</p>
</div>

</div>

</div>
<div class='section'>
<h2>Qualifying Statements
</h2>
<div class='field field_text'>
<h3>
Qualifying Statements
</h3>
<div class='FieldValue'>
<div class="content_para"><p>These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Implementation of the Guideline
</h2>
<div class='field field_text'>
<h3>
Description of Implementation Strategy
</h3>
<div class='FieldValue'>
<div class="content_para"><p>An implementation strategy was not provided.</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Implementation Tools
</h3>
<div class='FieldValue'>
Clinical Algorithm
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Healthcare Quality Report Categories
</h2>
<div class='field field_picklist-many'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Getting Better
</div>

</div>
<div class='field field_picklist-many'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>
<div class='FieldValue'>
Timeliness 
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information and Availability
</h2>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>University of Michigan Health System. Management of acute atrial fibrillation and atrial flutter in non-pregnant hospitalized adults. Ann Arbor (MI): University of Michigan Health System; 2014 May. 26 p.  [30 references]</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date Released
</h3>
<div class='FieldValue'>
2014 May
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Guideline Developer(s)
</h3>
<div class='FieldValue'>
University of Michigan Health System - Academic Institution
</div>

</div>
<div class='field field_text'>
<h3>
Source(s) of Funding
</h3>
<div class='FieldValue'>
<div class="content_para"><p>University of Michigan Health System</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Committee
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Atrial Fibrillation Guideline Team</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of Group That Authored the Guideline
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Team Leaders</em>: Jeffrey M. Rohde, MD, Internal Medicine; Thomas C. Crawford, MD, Cardiology</p>
<p><em>Team Members</em>: Sarah E. Hartley, MD, Internal Medicine; Sarah Hanigan, PharmD, Pharmacy Services; Jules Lin, MD, Thoracic Surgery; Lewis B. Morgenstern, MD, Neurology (Stroke); F. Jacob Seagull, PhD, Medical Education; David M. Somand, MD, Emergency Medicine; David H. Wesorick, MD, Internal Medicine; James B. Froehlich, MD (<em>Consultant</em>), Cardiology</p>
<p><em>Inpatient Clinical Guidelines Oversight</em>: Sarah E. Hartley, MD; David H. Wesorick, MD; F. Jacob Seagull, PhD</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.</p>
<p>No team member reported a conflict of interest.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Electronic copies: Available from the <a href="http://www.med.umich.edu/1info/FHP/practiceguides/afib.html" title="University of Michigan Health System Web site">University of Michigan Health System Web site</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Availability of Companion Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>None available</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Patient Resources
</h3>
<div class='FieldValue'>
<div class="content_para"><p>None available</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NGC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary was completed by ECRI Institute on June 29, 2014.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NGC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>
</div>

</div>

</div>
</body></html>